|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||49.59 - 51.25|
|52 Week Range||27.94 - 51.25|
|PE Ratio (TTM)||28.50|
|Earnings Date||Feb 21, 2018 - Feb 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.67|
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
Emergent (EBS) provides preliminary results for 2017 and its guidance for 2018. The results exceed management's outlook issued in November last year.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EBS. Over the last one-month, outflows of investor capital in ETFs holding EBS totaled $4.05 billion.
GAITHERSBURG, Md., Jan. 08, 2018-- Emergent BioSolutions Inc. today announced preliminary unaudited 2017 financial results and guidance for 2018.. Daniel J. Abdun-Nabi, president and chief executive officer ...
We take a look at four companies with a favorable Zacks Rank that performed well in 2017 and are likely to continue on the growth path in 2018 as well.
Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.
GAITHERSBURG, Md., Jan. 04, 2018-- Emergent BioSolutions Inc. today announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, ...
GAITHERSBURG, Md., Jan. 03, 2018-- Emergent BioSolutions Inc. announced today that a member of the company’ s senior management team will participate in the following investor conferences during the first ...
Sanofi (SNY) and Alnylam announced that the FDA has lifted the clinical hold placed on all ongoing studies of its hemophilia candidate, fitusiran.
Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Emergent BioSolutions, Inc. Here are 5 ETFs with the largest exposure to EBS-US. Comparing the performance and risk of Emergent BioSolutions, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
GAITHERSBURG, Md., Dec. 12, 2017-- Emergent BioSolutions Inc. today announced that it has been awarded a contract by the Department of National Defence valued at approximately $8 million to deliver Anthrasil ...
Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.
GAITHERSBURG, Md., Nov. 30, 2017-- Emergent BioSolutions Inc. today announced that the company will host an analyst and investor day on December 7, 2017 in New York City.. This event, which is designed ...
Nov.30 -- Andreas Treichl, chairman and chief executive officer at Erste Group Bank, discusses bitcoin and why he says central banks will not allow the cryptocurrency to happen. He speaks with Guy Johnson on “Bloomberg Markets: European Open.”